ArticleBiomaterials2018
Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease.
Abstract read
In one paragraph
Article in Biomaterials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
7.1field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 101 citations in OpenAlex.
- Water-triggered in-situ gelling phospholipid oil enema for enhanced budesonide delivery and mucosal healing in ulcerative colitis.International journal of pharmaceutics: X · 2026Article
- From triggers to interfaces: polymer-stabilized nano-co-crystals for robust mesalazine delivery in UC.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Clinical combination therapy for IBD and promising co-delivery strategies.Inflammopharmacology · 2026Review
- Synthetic mucus biomaterials enable localized therapeutic antibody delivery in inflammatory bowel disease.APL bioengineering · 2026Article
- Delivery Strategies and Clinical Significance of Oral Colon-targeted Drug Delivery Systems.AAPS PharmSciTech · 2026Review
- Selective Nanoparticulate Systems for Drug Delivery in Inflammatory Bowel Disease.Pharmaceutics · 2025Review
- Innovative triamcinolone acetonide microsuspension for Non-Invasive ocular management of inflammation.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025Article
- Advances in nanorobotics for gastrointestinal surgery: a new frontier in precision medicine and minimally invasive therapeutics.Journal of robotic surgery · 2025Review
- The mucosal protein corona in local nanoparticle drug delivery.Cell biomaterials · 2025Article
- Elevated levels of IRF1 and CASP1 as pyroptosis-related biomarkers for intestinal epithelial cells in Crohn's disease.Frontiers in immunology · 2025Article
- Nanomedicine: The new trend and future of precision medicine for inflammatory bowel disease.Chinese medical journal · 2024Review
- A Future Avenue of Treatment Ulcerative Colitis Targeting Macrophage Polarization: A Phytochemical Application.Crohn's & colitis 360 · 2024Article
- Hypotonic, gel-forming delivery system for vaginal drug administration.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Multiple Particle Tracking: A Method for Probing Biologically Relevant Mobility of Bacterial Extracellular Vesicles.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Locally Acting Budesonide-Loaded Solid Self-Microemulsifying Drug Delivery Systems (SMEDDS) for Distal Ulcerative Colitis.International journal of nanomedicine · 2024Article
- Nanoparticle-Based Drug Delivery Systems for Inflammatory Bowel Disease Treatment.Drug design, development and therapy · 2024Review
- Pulmonary delivery of mucus-traversing PF127-modified silk fibroin nanoparticles loading with quercetin for lung cancer therapy.Asian journal of pharmaceutical sciences · 2023Article
- Surface-anchored microbial enzyme-responsive solid lipid nanoparticles enabling colonic budesonide release for ulcerative colitis treatment.Journal of nanobiotechnology · 2023Article
- Injectable, Drug-Eluting Nanocrystals Prevent Fibrosis and Stricture Formation In Vivo.Gastroenterology · 2023Article
- Exosome-Based Regimen Rescues Endometrial Fibrosis in Intrauterine Adhesions Via Targeting Clinical Fibrosis Biomarkers.Stem cells translational medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Abhijit A DateThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N. Broadway, Baltimore, MD 21231, USA.
Gilad HalpertThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N. Broadway, Baltimore, MD 21231, USA.
Taarika BabuThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Jairo OrtizThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N. Broadway, Baltimore, MD 21231, USA.
Pranjali KanvindeThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA.
Peter DimitrionThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA.
Janani NarayanThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA.
Hannah ZierdenThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA.
Kalpana BetageriThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Olivia MusmannoThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Aaron A WiegandThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Xinglu HuangThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N. Broadway, Baltimore, MD 21231, USA.
Sanjeev GumberDivision of Pathology, Yerkes National Primate Research Center, Atlanta, GA 30322, USA.
Justin HanesThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N. Broadway, Baltimore, MD 21231, USA; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Electronic address: hanes@jhmi.edu.
Laura M EnsignThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N. Broadway, Baltimore, MD 21231, USA; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Electronic address: lensign@jhmi.edu.
Johns Hopkins Medicine · USJohns Hopkins University · USEmory National Primate Research Center
Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MInstitute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1MThe Role of gp120 on Cardiovascular Disease in People Living with HIVU54MD007601 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI Benjamin C. Fogelgren · 2017 to 2026
$59.5MWilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI Ji Yi · 1985 to 2026
$22.1MTRPA1 Physiology in Diabetes, Metabolic Syndrome, and MetabolismP20GM113134 · NIGMS · UNIVERSITY OF HAWAII AT MANOA · PI Michael A. Ortega · 2017 to 2026
$21.5MTissue pharmacology imaging and modelingU19AI113127 · NIAID · JOHNS HOPKINS UNIVERSITY · PI MCGOWAN, IAN MICHAEL · 2014 to 2018
$20.7MMucus-Penetrating Nanoparticle Containing Enemas for Ulcerative ColitisR01DK107806 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI ENSIGN, LAURA, HANES, JUSTIN S. · 2016 to 2019
$1.5MMucus-penetrating nanoparticles for sustained microbicide deliveryR33AI079740 · NIAID · JOHNS HOPKINS UNIVERSITY · PI HANES, JUSTIN S. · 2010 to 2012
$1.4MNCATS NIH HHS UL1 TR001079NEI NIH HHS P30 EY001765NIAID NIH HHS R33 AI079740NIAID NIH HHS U19 AI113127NIDDK NIH HHS R01 DK107806NIGMS NIH HHS P20 GM113134NIH HHS P51 OD011132NIMHD NIH HHS U54 MD007601
Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory gastrointestinal disorder that affects more than 1 million individuals in the USA. Local therapy with enema formulations, such as micronized budesonide (Entocort
Indexed as
Drug Delivery SystemsAnimalsAnti-Inflammatory AgentsBudesonideColonDrug CompoundingEnemaInflammatory Bowel DiseasesMaleMiceMice, Inbred C57BLMucusNanoparticlesPoloxamerPolystyrenesSuspensionsAnti-Inflammatory AgentsBudesonidePoloxamerPolystyrenesSuspensionsTrinitrobenzenesulfonic AcidBudesonideColitisPluronic F127Trinitrobenzenesulfonic acid (TNBS)Wet-milling
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.